Pharmacovigilance has a critical role in promoting patient safety for both recently medications that have been introduced and those that are well-known brands. In the context of clinical trials, pharmaceutical operations are tightly regulated; nonetheless, post-marketing adverse event Reporting is not properly enforced or put into practice. As a result, it is estimated that 90% of adverse occurrences related to medications on the market are not reported. It is consequently particularly difficult to identify drug safety risks in individuals with complicated disorders and several comorbidities.